AstraZeneca (AZN) is set to acquire U.S. biotech company FibroGen’s (FGEN) China unit for $160 million to expand its presence in the country.

AstraZeneca walked away from the bulk of its roxadustat partnership with FibroGen—though the pharma at the time decided to ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be ...

The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, ...

Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently ...

Despite the potential benefits of early detection and increasing treatment options for Alzheimer's disease and related ...

An unusual swelling in the legs and feet could indicate the onset of kidney damage. When the kidneys struggle to eliminate ...

Dr Ravinder K Gupta, Dr Akhilpreet Kaur Anemia is a serious global public health problem that particularly affects young ...

Well over 10 thousand people from 9 tribal districts of Rajasthan have been found suffering from serious Sickle Cell Disease.  This has been revealed in a recent report of the Medical and Health ...